Maxcyte | CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting

Gaithersburg, Maryland – November 9, 2020: MaxCyte, Inc., a global cell-based therapies and life sciences company, announces that its subsidiary CARMA Cell Therapies will share results of a detailed phenotypic and functional characterization of MCY-M11, its lead anti-mesothelin CAR-PBMC cell therapy candidate, at the Society for Immunotherapy of Cancer’s (SITC) 35th anniversary meeting. The Virtual Scientific Program begins today and...

READ MORE Maxcyte | CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting

Monte Carlo Yachts Becomes First Yacht Builder to Feature Raymarine DockSense Alert

Luxury Yacht Builder Unveils Assisted Docking Solution on the New MCY 76 Skylounge ARLINGTON, Va. 5th October 2020 – FLIR Systems, Inc. announced today its Raymarine brand has collaborated with luxury yacht builder Monte Carlo Yachts to be the first to factory install Raymarine DockSense® Alert on their new yacht, the Monte Carlo MCY 76 Skylounge. DockSense Alert provides the...

READ MORE Monte Carlo Yachts Becomes First Yacht Builder to Feature Raymarine DockSense Alert

MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting

Gaithersburg, Maryland – May 18, 2020: – MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announces that clinical data from the first three cohorts of the ongoing Phase I dose-escalation trial demonstrating safety of MCY-M11 and feasibility of one-day manufacturing will be shared at the American Society of Clinical Oncology’s (ASCO) upcoming annual meeting. The ASCO20 Virtual Scientific Program...

READ MORE MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting

Maxcyte | MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform

–      No dose-limiting toxicities or safety concerns observed in first cohort of treated patients–      Feasibility of streamlined, faster CAR therapy manufacturing process confirmed–      Dosing initiated in second cohort of patients Gaithersburg, Maryland – May 8, 2019: MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it has initiated dosing for...

READ MORE Maxcyte | MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform